A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices
ConclusionPatients receiving pegfilgrastim OBI had a lower incidence of FN compared with those receiving alternatives. The OBI was associated with improved adherence to and compliance with clinically recommended G-CSF prophylaxis.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Filgrastim | Lung Cancer | Lymphoma | Neulasta | Neupogen | Non-Hodgkin's Lymphoma | Study